| scholarly article | Q13442814 |
| P50 | author | Hagop Kantarjian | Q60394812 |
| P2093 | author name string | Jean-Pierre J Issa | |
| P2860 | cites work | DNA methylation as a therapeutic target in cancer | Q36760984 |
| Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines | Q37066258 | ||
| Rational combinations using HDAC inhibitors | Q37512911 | ||
| Reprogramming of a melanoma genome by nuclear transplantation | Q37521263 | ||
| An elaborate pathway required for Ras-mediated epigenetic silencing | Q40062561 | ||
| A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia | Q40102480 | ||
| Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides | Q40110178 | ||
| Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. | Q40309778 | ||
| Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. | Q40361515 | ||
| Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate | Q40508930 | ||
| Cellular differentiation, cytidine analogs and DNA methylation | Q42242732 | ||
| Cancer DNA methylation: molecular mechanisms and clinical implications | Q42573635 | ||
| Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment | Q44155422 | ||
| Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation | Q44364520 | ||
| Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies | Q44646952 | ||
| An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients | Q46740971 | ||
| Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors | Q46958949 | ||
| Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). | Q46979100 | ||
| Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo | Q48693524 | ||
| Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. | Q53606125 | ||
| Increased cytosine DNA-methyltransferase activity during colon cancer progression | Q72832112 | ||
| Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms | Q79734535 | ||
| Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome | Q80538299 | ||
| Effect of cytarabine and decitabine in combination in human leukemic cell lines | Q80624812 | ||
| DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia | Q83364381 | ||
| DNA methylation patterns and epigenetic memory | Q22065780 | ||
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 | ||
| DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome | Q24644436 | ||
| Chromatin modifications and their function | Q27861067 | ||
| The genomic landscapes of human breast and colorectal cancers | Q27861078 | ||
| Lessons from hereditary colorectal cancer | Q28131788 | ||
| Epigenetic reprogramming in mammalian development | Q28212171 | ||
| DNMT1 and DNMT3b cooperate to silence genes in human cancer cells | Q28212826 | ||
| Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells | Q28245307 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| The epigenomics of cancer | Q28289975 | ||
| Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study | Q28301602 | ||
| Dissecting direct reprogramming through integrative genomic analysis | Q29614211 | ||
| Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer | Q29615066 | ||
| Stability and flexibility of epigenetic gene regulation in mammalian development | Q29615922 | ||
| Myelodysplastic syndromes. | Q31131701 | ||
| Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers | Q33381378 | ||
| Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells | Q33689112 | ||
| Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients | Q33891633 | ||
| Nuclear cloning and epigenetic reprogramming of the genome | Q34086441 | ||
| Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 | ||
| Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience | Q34187884 | ||
| Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. | Q34204305 | ||
| Multiple new phenotypes induced in and 3T3 cells treated with 5-azacytidine | Q34418477 | ||
| Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia | Q34553286 | ||
| Decitabine--bedside to bench | Q34571780 | ||
| Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia | Q34659942 | ||
| A pilot pharmacokinetic study of oral azacitidine | Q34786094 | ||
| Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia | Q35848726 | ||
| Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation | Q35939534 | ||
| Epigenetic changes in solid and hematopoietic tumors. | Q36279348 | ||
| Epigenetic therapy of cancer: past, present and future | Q36399557 | ||
| Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia | Q36445926 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | DNA methylation | Q874745 |
| P304 | page(s) | 3938-3946 | |
| P577 | publication date | 2009-06-09 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Targeting DNA methylation | |
| P478 | volume | 15 |
| Q38588894 | 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. |
| Q36159688 | A high-throughput screen of inactive X chromosome reactivation identifies the enhancement of DNA demethylation by 5-aza-2'-dC upon inhibition of ribonucleotide reductase |
| Q38817997 | A novel epigenetic mechanism regulating hyaluronan production in pancreatic cancer cells |
| Q33918412 | A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. |
| Q49711997 | AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo |
| Q37737945 | Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. |
| Q34360642 | Aberrant WNT/β-catenin signaling in parathyroid carcinoma |
| Q37089505 | Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC |
| Q37403008 | Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent |
| Q34802527 | An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer |
| Q24622700 | An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes |
| Q39214234 | Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression |
| Q34031951 | Application of epigenome-modifying small molecules in induced pluripotent stem cells |
| Q90533555 | BRD4 interacts with PML/RARα in acute promyelocytic leukemia |
| Q42573635 | Cancer DNA methylation: molecular mechanisms and clinical implications |
| Q34279875 | Cancer chemoprevention by dietary polyphenols: promising role for epigenetics |
| Q38203281 | Cancer chemoprevention by traditional chinese herbal medicine and dietary phytochemicals: targeting nrf2-mediated oxidative stress/anti-inflammatory responses, epigenetics, and cancer stem cells. |
| Q35348043 | Cancer epigenetics: linking basic biology to clinical medicine. |
| Q51213761 | Challenges in developing novel DNA methyltransferases inhibitors for cancer therapy. |
| Q34038652 | Chromatin proteins and modifications as drug targets |
| Q34101643 | Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. |
| Q90272769 | Chromatin structure regulates cancer-specific alternative splicing events in primary HPV-related oropharyngeal squamous cell carcinoma |
| Q35887221 | Chromatin-targeting small molecules cause class-specific transcriptional changes in pancreatic endocrine cells. |
| Q90239923 | Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms |
| Q38926364 | Combined analysis of DNA methylation and cell cycle in cancer cells |
| Q36871721 | Concise drug review: azacitidine and decitabine |
| Q24597977 | CpG island methylation in colorectal cancer: past, present and future |
| Q34636402 | CpG methylation recruits sequence specific transcription factors essential for tissue specific gene expression |
| Q34195077 | Current limitations and future opportunities for epigenetic therapies. |
| Q37883042 | Cytosine methyltransferases as tumor markers |
| Q38979940 | DNA Hypomethylating Drugs in Cancer Therapy |
| Q38833395 | DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects. |
| Q39003558 | DNA Methyltransferase Inhibitors: Development and Applications. |
| Q37148677 | DNA methylation as clinically useful biomarkers-light at the end of the tunnel |
| Q38018995 | DNA methylation biomarkers in cancer: progress towards clinical implementation |
| Q37961740 | DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status |
| Q37776026 | DNA methylation profiling in cancer |
| Q48126042 | DNA methylation reprogramming of human cancer cells by expression of a plant 5-methylcytosine DNA glycosylase. |
| Q35647894 | DNA methylation topology: potential of a chromatin landmark for epigenetic drug toxicology |
| Q88511739 | DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine |
| Q28544885 | DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status |
| Q28484901 | DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis |
| Q38049175 | DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies |
| Q90573547 | DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation |
| Q40579130 | DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. |
| Q39620587 | Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. |
| Q33678040 | Demethylating Agents in the Treatment of Cancer |
| Q38719020 | Demethylating and anti-hepatocarcinogenic potential of hesperidin, a natural polyphenol of Citrus juices. |
| Q39690744 | Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription |
| Q35687461 | Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine |
| Q36576975 | Dietary components as epigenetic-regulating agents against cancer |
| Q38818485 | Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges |
| Q34476181 | Different effects of valproic acid on photoreceptor loss in Rd1 and Rd10 retinal degeneration mice |
| Q33762936 | Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies |
| Q38912946 | Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome |
| Q42933412 | Drug-loaded biodegradable microspheres for image-guided combinatory epigenetic therapy in cells |
| Q87944354 | Effect of Qinghuang Powder () Combined with Bupi Yishen Decoction () in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation |
| Q37962013 | Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers |
| Q35835233 | Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. |
| Q34496410 | Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2 |
| Q42367979 | Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer |
| Q89996538 | Epigenetic Modification and Differentiation Induction of Malignant Glioma Cells by Oligo-Fucoidan |
| Q33559964 | Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells |
| Q24608659 | Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine |
| Q38051195 | Epigenetic aspects of MDS and its molecular targeted therapy |
| Q38125641 | Epigenetic cancer prevention mechanisms in skin cancer |
| Q37969665 | Epigenetic cancer therapy: rationales, targets and drugs |
| Q34532204 | Epigenetic changes in Basal Cell Carcinoma affect SHH and WNT signaling components |
| Q33767309 | Epigenetic changes in the myelodysplastic syndrome. |
| Q37116613 | Epigenetic changes: a common theme in acute myelogenous leukemogenesis |
| Q53098086 | Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines. |
| Q37941536 | Epigenetic drug discovery: targeting DNA methyltransferases |
| Q37800011 | Epigenetic modifications as therapeutic targets |
| Q34129835 | Epigenetic modifications by dietary phytochemicals: implications for personalized nutrition |
| Q45976173 | Epigenetic modifiers: basic understanding and clinical development. |
| Q36786757 | Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. |
| Q37962586 | Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance |
| Q28067666 | Epigenetic polypharmacology: from combination therapy to multitargeted drugs |
| Q27694612 | Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response |
| Q36287972 | Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications |
| Q34621606 | Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer |
| Q36053915 | Epigenetic synergy between decitabine and platinum derivatives |
| Q91361596 | Epigenetic therapy in immune-oncology |
| Q38121995 | Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases. |
| Q100762264 | Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency |
| Q84597148 | Epigenetic variation and cellular Darwinism |
| Q37964702 | Epigenetic-based therapies in cancer: progress to date |
| Q27010637 | Epigenetics advancing personalized nanomedicine in cancer therapy |
| Q34085532 | Epigenetics and cancer |
| Q27014984 | Epigenetics meets radiation biology as a new approach in cancer treatment |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q38017604 | Epigenetics of regional lymph node metastasis in solid tumors. |
| Q37785109 | Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics |
| Q58034903 | Epigenetik in der Onkologie |
| Q38660042 | Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. |
| Q41871930 | Epigenomics: Pioneering a New Frontier in Cancer Research |
| Q26773055 | Epithelial-Mesenchymal Transition and Breast Cancer |
| Q36956610 | Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. |
| Q36290974 | Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells |
| Q41192395 | Functional study of hENT1 on SKM-1 cell resistance to decitabine |
| Q90633236 | Gene-Specific Targeting of DNA Methylation in the Mammalian Genome |
| Q35911266 | Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. |
| Q58321447 | Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions |
| Q92086744 | Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia |
| Q36654140 | Genomic impact of transient low-dose decitabine treatment on primary AML cells |
| Q33723714 | Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission |
| Q42686182 | Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial |
| Q37569819 | Induction of Epigenetic Alteration by CPUK02, An Ent- kaurenoid Derivative of Stevioside. |
| Q35147669 | Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis |
| Q38644511 | Inhibition studies of DNA methyltransferases by maleimide derivatives of RG108 as non-nucleoside inhibitors. |
| Q31101656 | Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity |
| Q42552522 | Ischemia dysregulates DNA methyltransferases and p16INK4a methylation in human colorectal cancer cells |
| Q92003943 | Key actors in cancer therapy: epigenetic modifiers |
| Q34275371 | Leukaemogenesis: more than mutant genes |
| Q39687085 | Long-term stability of demethylation after transient exposure to 5-aza-2'-deoxycytidine correlates with sustained RNA polymerase II occupancy |
| Q28589092 | Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis |
| Q36813932 | Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer |
| Q33999539 | Mechanisms of resistance to decitabine in the myelodysplastic syndrome. |
| Q37257390 | Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies |
| Q33862548 | Mixed lineage leukemia: histone H3 lysine 4 methyltransferases from yeast to human |
| Q30570945 | Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives |
| Q37957798 | Molecular alterations in hepatocarcinogenesis induced by dietary methyl deficiency |
| Q38011287 | Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor |
| Q38927510 | Multiple regulations of Keap1/Nrf2 system by dietary phytochemicals |
| Q92502884 | Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference |
| Q38080414 | Perspectives on natural product epigenetic modulators in chemical biology and medicine. |
| Q33393266 | Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. |
| Q37469412 | Plant phytochemicals as epigenetic modulators: role in cancer chemoprevention |
| Q36975817 | Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia |
| Q42695542 | Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin |
| Q58710647 | Profiling DNA Methylation Based on Next-Generation Sequencing Approaches: New Insights and Clinical Applications |
| Q37962596 | Promises and challenges of anticancer drugs that target the epigenome |
| Q51034997 | Promoter methylation and gene polymorphism are two independent events in regulation of GSTP1 gene expression. |
| Q36862682 | Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer. |
| Q36015018 | RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia |
| Q36251573 | Repeated assessment by high-throughput assay demonstrates that sperm DNA methylation levels are highly reproducible |
| Q37102684 | Restoration of the methylation status of hypermethylated gene promoters by microRNA-29b in human breast cancer: A novel epigenetic therapeutic approach |
| Q34839397 | S100A4 expression in xenograft tumors of human carcinoma cell lines is induced by the tumor microenvironment |
| Q39011822 | SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome |
| Q58743091 | SMMDB: a web-accessible database for small molecule modulators and their targets involved in neurological diseases |
| Q33425338 | Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study |
| Q37946239 | Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview |
| Q42700953 | Selective DNA methylation in cancers controls collateral damage induced by large structural variations |
| Q29617301 | Selective inhibition of tumor oncogenes by disruption of super-enhancers |
| Q36776566 | Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells |
| Q34465331 | Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics |
| Q36430196 | Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development |
| Q33600124 | Tackling the methylome: recent methodological advances in genome-wide methylation profiling |
| Q55435258 | Targeting DNA Methyltranferases in Urological Tumors. |
| Q34258037 | Targeting DNA methylation for epigenetic therapy |
| Q35214645 | Targeting components of epigenome by small molecules |
| Q88221125 | Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents--implications for cancer treatment and chemoprevention |
| Q92179985 | Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer |
| Q38821103 | Targeting the cancer epigenome for therapy |
| Q53201323 | Targeting the epigenome for treatment of cancer. |
| Q37984122 | Targeting the epigenome in ovarian cancer. |
| Q36001852 | Targeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cells |
| Q35897271 | The 3D tissue microenvironment modulates DNA methylation and E-cadherin expression in squamous cell carcinoma. |
| Q37911496 | The application of delivery systems for DNA methyltransferase inhibitors |
| Q64077338 | The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes |
| Q28389296 | The complexity of the Nrf2 pathway: beyond the antioxidant response |
| Q35985465 | The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression |
| Q90322264 | The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine |
| Q37808106 | The epigenome as a therapeutic target in prostate cancer |
| Q36833557 | The myelodysplastic syndrome as a prototypical epigenetic disease |
| Q37965484 | The potential role of nutritional genomics tools in validating high health foods for cancer control: broccoli as example |
| Q38119782 | The promise and failures of epigenetic therapies for cancer treatment |
| Q44294975 | The promise of epigenetic therapies in treatment of idiopathic pulmonary fibrosis |
| Q35988523 | Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase |
| Q37848839 | Therapeutic prospects for epigenetic modulation |
| Q38729313 | Transcriptional Selectivity of Epigenetic Therapy in Cancer. |
| Q35851931 | Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells |
| Q35085782 | Translational application of epigenetic alterations: ovarian cancer as a model |
| Q50089369 | Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas |
| Q48973690 | Trimethylaurintricarboxylic acid inhibits human DNA methyltransferase 1: insights from enzymatic and molecular modeling studies |
| Q37774865 | Tumor-initiating and -propagating cells: cells that we would like to identify and control |
| Q93189824 | Understanding Cancer Through the Lens of Epigenetic Inheritance, Allele-Specific Gene Expression, and High-Throughput Technology |
| Q38235662 | Update on the pharmacotherapy for myelodysplastic syndromes. |
| Q35479045 | WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix |
| Q37962016 | Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors |
| Q89862635 | [Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors] |
Search more.